Making sense of asthma

Bibliography

• VVEISS K: The impact of pharmacologic therapy on the costs of asthma. Allergy Proc. (1994) 15:189–192.
   PubMedGoogle Scholar
• LANDER ES: The new genomics: global views of biology. Science (1996) 274:536–539.
   PubMed Web of Science ®Google Scholar
• CHIANG MY, CHAN H, ZOUNES MA et al.: Antisense oligonucleotides inhibit ICAM expression by two dis-tinct mechanisms. J. Biol. Chem. (1991) 266:18162–18171.
   PubMed Web of Science ®Google Scholar
• SPROAT BS: Chemistry and applications of oligonu-cleotide analogues. J. Biotech. (1995) 41:221–238.
   PubMed Web of Science ®Google Scholar
• SCANLON KJ, OHTA Y, ISHIDA H et al.: Oligonucleotide-mediated modulation of mammalian gene expression. FASEB (1995) 9:1288–1296.
   PubMed Web of Science ®Google Scholar
• CROOKE ST: Progress in antisense therapeutics. Haema-tol. Pathol (1995) 9:59–72.
   PubMedGoogle Scholar
• BAYEVER E: Systemic administration of a phos-phorothioate oligonucleotide with a sequence comple-mentary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a Phase I trial. Antisense Res. Dev. (1993) 3:383–390.
   PubMedGoogle Scholar
• BENNETT CF, CHIANG MY, CHAN H et al.: Cationic lipids enhance cellular uptake and activity of phos-phorothioate antisense oligonucleotides. Mol. Pharr-1'1a-col. (1992) 41:1023–1033.
   Google Scholar
• NYCE JVV, METZGER WJ: DNA antisense therapy for asthma in an animal model. Nature (1996) 385:721–725.
   Web of Science ®Google Scholar
• DRIVER AG, KUKOLY CA, ALT S, MUSTAFA SJ: Adenosine in bronchoalveolar lavage fluid in asthma. Am. Rev. Respk. Dis. (1993) 148:91–97.
   PubMed Web of Science ®Google Scholar
• ALI S, MUSTAFA SJ, METZGER WJ: Adenosine receptor mediated bronchoconstriction and bronchial hyperre-sponsiveness in allergic rabbit model. Am. J. Physiol (1994) 2661271–L277.
   Google Scholar
• CHURCH MK, HOLGATE ST: Adenosine in the asthmatic lung. Prog. Clin. Biol. Res. (1988) 263:159–166.
   PubMedGoogle Scholar
• NORTHOVER AM, NORTHOVER BJ: Degranulation of rat omental mast-cells by Al receptor agonists in vitro. Med. Inflamm. (1996) 5:341–345.
   PubMed Web of Science ®Google Scholar
• FOZARD JR, PFANNKUCHE HJ, SCHUURMAN HJ: Mast-cell degranulation following adenosine A3 receptor activa-tion in rats. Eur. J. Pharmacol (1996) 298:293–297.
   PubMed Web of Science ®Google Scholar
• LINDEN J: Cloned adenosine A3 receptors: pharma-cological properties, species differences and receptor functions. Trends Pharmacol Sci. (1994) 15:298–306.
   PubMed Web of Science ®Google Scholar
• FENSTER MS, DULING BR: Activation of adenosine A2Areceptor inhibits adenosine A3 receptor-mediated mast-cell degranulation. Circulation (1996) 94:SS2483.
   Google Scholar
• FEOKTISTOV I, BIAGGIONI I: Adenosine A2B receptorsevoke interleukin-8 secretion in human mast-cells - an enprofylline-sensitive mechanism with implications for asthma. J. Clin. Invest. (1995) 96:1979–1986.
   PubMed Web of Science ®Google Scholar
• POLOSA R, NG WH, CRIMI N et al.: Release of mast cellderived mediators after endobronchial adenosine chal-lenge in asthma. Am. J. Respir. Grit. Care Med. (1995) 151:624–629.
   PubMed Web of Science ®Google Scholar
• PAUWELS R, JOOS GF, KIPS JC, PELEMAN RA: Mechanisms of adenosine-induced bronchoconstriction - an animal-model. Drug Dev. Res. (1993) 28(3):318–321.
   Web of Science ®Google Scholar
• DRIVER AG, KUKOLY CA, METZGER WJ, MUSTAFA SJ: Bronchial challenge with adenosine causes the release of serum neutrophil chemotactic factor in asthma. Am. Rev. Respir. Dis. (1991) 143:1002–1007.
   PubMed Web of Science ®Google Scholar
• MEADE CJ, MIERAU J, LEON I, ENSINGER HA: In vivo role of the adenosine A3 receptor: N6-2-(4-amino-phenyl) ethyladenosine induces bronchospasm in BDE rats by a neurally mediated mechanism involving cells resembling mast cells. J. Pharmacol Exp. Ther. (1996) 279:1148–1156.
   PubMed Web of Science ®Google Scholar
• CRONSTEIN BN, DAGUMA L, NICHOLS D, HUTCHINSON AJ, WILLIAMS M: The adenosine/neutrophil paradox resolved: human neutrophils possess both A1 and A2 receptors that promote chemotaxis and inhibit 02 gen-eration, respectively.j Clin. Invest. (1990) 85:1150–1157.
   PubMed Web of Science ®Google Scholar
• CRONSTEIN BN, LEVIN RI, PHILIPS M et al.: Neutrophil adherence to endothelium is enhanced via adenosine Ai receptors and inhibited via adenosine A2 receptors. Immunol. (1992) 148:2201–2206.
   Web of Science ®Google Scholar
• WALKER BAM, ROCCHINI C, BOONE RH, IP S, JACOBSON MA: Adenosine A2a receptor activation delays apoptosis in human neutrophils. ImmunoL (1997) 158:2926–2931.
   Web of Science ®Google Scholar
• PEACHELL PT, LICHTENSTEIN LM, SCHLEIMER RP: Differ-ential regulation of human basophil and lung mast-cell function by adenosine. J. PharmacoL Exp. Ther. (1991) 256:717–726.
   PubMed Web of Science ®Google Scholar
• WALKER BAM, JACOBSON MA, KNIGHT DA eta].: Adeno-sine A3 receptor expression and function in eosino-phils. Am. J. Respir Cell Mol. Biol. (1997) 16:531–537.
   Google Scholar
• GERWINS P, FREDHOLM BB: Stimulation of adenosine Ai receptors and bradykinin receptors which act via dif-ferent G-proteins, synergistically raises inositol 1,4,5-triphosphate and intracellular calcium in DDT1MF2 smooth muscle cells. Proc. Natl. Acad. Sci. USA (1992) 89:7330–7334.
   PubMed Web of Science ®Google Scholar
• GOBRAN LL, ROONEY SA: Adenosine Ai receptor medi-ated inhibition of surfactant secretion in rat type II pneumocytes. Am. J. Physic)]. (1990) 258:L45–L51.
   Web of Science ®Google Scholar
• NICHOLSON CD, CHALLISS RAJ, SHAHID M: Differentialmodulation of tissue function and therapeutic potentia - lof selective inhibitors of cyclic nucleotide phosphodi-esterase isoenzymes. Trends Pharmacol. Sci. (1991) 12:19–27.
   PubMed Web of Science ®Google Scholar
• TEIXEIRA MM, GRISTWOOD RW, COOPER N, HELLEWELLPG: Phosphodiesterase (PDE) 4 inhibitors: anti-inflam-matory drugs of the future? Trends Pharmacol Sci. (1997) 18:164-170.
   Google Scholar
• HAY DWP, TORPHY TJ, UNDEM BJ: Cysteinyl leuk-otrienes in asthma: old mediators up to new tricks. Trends Pharmacol Sci. (1995) 16:304–309.
   PubMed Web of Science ®Google Scholar
• TAYLOR IK, O'SHAUGHNESSY KM, FULLER RW, DOLLERYCT: Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet (1991) 337:690–694.
   Google Scholar
• ICHINOSE M, NAKAJIMA N, TAKAHASHI T et al: Protection against bradykinin-induced bronchoconstriction in asthmatic patients by neurokinin receptor antagonist. Lancet (1992) 340:1248–1251.
   PubMed Web of Science ®Google Scholar
• BARNES PJ: Cytokines as mediators of chronic asthma. Am. J. Respir. Grit. Care Med. (1994) 150:S42–S49.
   PubMed Web of Science ®Google Scholar
• VAN ACKER FAA, VOSS H-P, TIMMERMAN H: Chem okines:structure receptors and functions. A new target for inflammation and asthma therapy?Med. Inflamm. (1996) 5:393–416.
   Google Scholar
• SHIRAKAWA T, ENOMOTO T, SHIMAZU S-I, HOPKIN JM:The inverse association between tuberculin and atopic disorder. Science (1997) 275:77–79.
   PubMed Web of Science ®Google Scholar
• MONTEFORT S, HOLGATE ST, HOWARTH PH: Leucocyte-endothelial adhesion molecules and their role in bron-chial asthma and allergic rhinitis. Eur. Respir. J. (1994) 6:1044–1054.
   Web of Science ®Google Scholar
• KORTHUIS RJ, ANDERSON DC, GRANGER DN: Role of neutrophil-endothelial cell adhesion in inflammatory disorders. J. Grit. Care (1994) 9:47–71.
   Google Scholar
• WEGNER CD, GUNDEL RH, REILLY P et al.: Intercellularadhesion molecule-1 (ICAM-1) in the pathogenesis of asthma. Science (1990) 247:456–459.
   PubMed Web of Science ®Google Scholar